Detection and in silico evaluation of undeclared venlafaxine and clomethiazole in a counterfeit herbal product marketed for alcohol withdrawal syndrome
Journal of Pharmaceutical and Biomedical Analysis · 2026
DOI: 10.1016/j.jpba.2025.117189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2026. Verfasst von Zeynep Arslan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science, Institute of Forensic Sciences and Legal Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye. Electronic address: zeyn…. Hauptthemen laut MEDLINE: Venlafaxine Hydrochloride, Counterfeit Drugs, Substance Withdrawal Syndrome, Chlormethiazole. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Herbal products, increasingly popular for various health conditions, pose significant public health concerns due to their frequent adulteration with undeclared pharmaceutical ingredients. Such adulteration is alarming, as these readily accessible products can lead to severe health consequences, including direct poisoning or adverse drug interactions. In this study, we investigated a counterfeit herbal product, marketed for alcohol withdrawal syndrome, following a consumer complaint. Gas chromatography-mass spectrometry (GC-MS) analysis revealed the presence of two prescription-only drugs, clomethiazole and venlafaxine. The analytical method for both compounds was validated to ensure accurate quantification. Within a 530.14 mg capsule, a staggering amount of approximately 252 mg of venlafaxine and 70 mg of clomethiazole were detected. To further evaluate the potential health risks, molecular docking and ADME (Absorption, Distribution, Metabolism, Excretion) prediction studies were conducted with serotonergic targets (SERT and 5-HT2A), GABAA receptors, and key metabolic enzymes (CYP3A4, CYP2D6, CYP2E1). This study is the first to assess the potential risks posed by the co-existence of clomethiazole and venlafaxine in a counterfeit herbal product, utilizing both chemical analysis and silico methods. Our findings unequivocally demonstrate that adulterated products carry serious risks of poisoning, drug interactions, and accidents. The potential for serious adverse events is further amplified when these adulterated products are consumed by individuals in professions requiring high levels of motor coordination, such as drivers, who unknowingly ingest substances like clomethiazole and venlafaxine that impair motor functions. This underscores the urgent need for stricter regulatory oversight and enhanced forensic scrutiny of herbal products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Science, Institute of Forensic Sciences and Legal Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye. Electronic address: zeynepars.96@gmail.com.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Türkiye.
- Department of Science, Institute of Forensic Sciences and Legal Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
Zitieren
APA
Arslan, Z., Şenol, H., Yayla, M., & Turkmen, Z. (2026). Detection and in silico evaluation of undeclared venlafaxine and clomethiazole in a counterfeit herbal product marketed for alcohol withdrawal syndrome. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2025.117189
Vancouver
Arslan Z, Şenol H, Yayla M, Turkmen Z. Detection and in silico evaluation of undeclared venlafaxine and clomethiazole in a counterfeit herbal product marketed for alcohol withdrawal syndrome. Journal of Pharmaceutical and Biomedical Analysis. 2026. doi:10.1016/j.jpba.2025.117189
BibTeX
@article{Arslan2026,
author = {Arslan, Zeynep and Şenol, Halil and Yayla, Murat and Turkmen, Zeynep},
title = {Detection and in silico evaluation of undeclared venlafaxine and clomethiazole in a counterfeit herbal product marketed for alcohol withdrawal syndrome},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2026},
doi = {10.1016/j.jpba.2025.117189}
}
EUVIMED